Table 1.
Baseline demographic and clinical characteristics in MVI− and MVI + groups
| Variable | Total (n = 35) | MVI− (n = 17) | MVI + (n = 18) | P-value |
|---|---|---|---|---|
| Age (years) | 54.0 (42.0, 62.0) | 54.0 (48.0, 64.0) | 51.0 (40.5, 61.5) | 0.275 |
| Gender | 0.554 | |||
| Male | 31 (88.6%) | 14 (82.4%) | 17 (94.4%) | |
| Female | 4 (11.4%) | 3 (17.6%) | 1 (5.6%) | |
| HBsAg | 1.000 | |||
| Negative | 3 (8.6%) | 1 (5.9%) | 2 (11.1%) | |
| Positive | 32 (91.4%) | 16 (94.1%) | 16 (88.9%) | |
| AFP (ng/mL) | 0.012 | |||
| ≥ 400 | 10 (28.6%) | 16 (94.1%) | 9 (50.0%) | |
| < 400 | 25 (71.4%) | 1 (5.9%) | 9 (50.0%) | |
| Tumor size (cm) | 4.0 (3.1, 5.1) | 3.5 (3.1, 5.1) | 4.0 (3.0, 5.5) | 0.974 |
| Tumor number | 0.977 | |||
| Solitary | 34 (97.1%) | 16 (94.1%) | 18 (100.0%) | |
| Multiple | 1 (2.9%) | 1 (5.9%) | 0 (0.0%) | |
| Child–Pugh class | 1.000 | |||
| A | 33 (94.3%) | 16 (94.1%) | 17 (94.4%) | |
| B | 2 (5.7%) | 1 (5.9%) | 1 (5.6%) | |
| Liver cirrhosis | 1.000 | |||
| Absence | 12 (34.3%) | 6 (35.3%) | 6 (33.3%) | |
| Presence | 23 (65.7%) | 11 (64.7%) | 12 (66.7%) | |
| BCLC stage | 0.500 | |||
| 0–A | 26 (74.3%) | 14 (82.4%) | 12 (66.7%) | |
| B–C | 9 (25.7%) | 3 (17.6%) | 6 (33.3%) | |
| TNM stage | 0.369 | |||
| 0–I | 30 (85.7%) | 16 (94.1%) | 14 (77.8%) | |
| II–III | 5 (14.3%) | 1 (5.9%) | 4 (22.2%) | |
| Imaging tumor thrombus | 0.062 | |||
| Absence | 30 (85.7%) | 17 (100.0%) | 13 (72.2%) | |
| Presence | 5 (14.3%) | 0 (0.0%) | 5 (27.8%) | |
| Tumor necrosis | 0.148 | |||
| Absence | 26 (74.3%) | 15 (88.2%) | 11 (61.1%) | |
| Presence | 9 (25.7%) | 2 (11.8%) | 7 (38.9%) | |
| Tumor differentiation | 1.000 | |||
| Well or moderate | 30 (85.7%) | 15 (88.2%) | 15 (83.3%) | |
| Poor | 5 (14.3%) | 2 (11.8%) | 3 (16.7%) | |
| Ascites | 1.000 | |||
| Absence | 34 (97.1%) | 17 (100.0%) | 17 (94.4%) | |
| Presence | 1 (2.9%) | 0 (0.0%) | 1 (5.6%) | |
| ALB (g/L) | 40.2 (37.5, 41.6) | 40.4 (38.4, 41.8) | 39.5 (36.8, 41.3) | 0.530 |
| TBIL (μmol/L) | 14.4 (11.4, 21.1) | 12.7 (11.3, 19.4) | 16.1 (11.8, 22.7) | 0.322 |
| ALT (U/L) | 33.0 (25.0, 50.0) | 33.0 (25.0, 50.0) | 33.0 (26.0, 46.5) | 0.843 |
| AST (U/L) | 33.0 (25.0, 40.5) | 34.0 (26.0, 41.0) | 32.0 (25.3, 40.0) | 0.779 |
| PT (s) | 12.1 (11.5, 13.1) | 12.1 (11.5, 12.3) | 12.1 (11.5, 13.3) | 0.667 |
| PLT (109/L) | 164.0 (111.0, 206.0) | 165.0 (150.0, 200.0) | 154.5 (104.25, 203.0) | 0.729 |
Continuous variables are presented as median (inter-quartile range, IQR) unless noted otherwise. Categorical variables are presented as n (%)
AFP alpha-fetoprotein, HBsAg hepatitis B surface antigen, ALB albumin, TBIL total bilirubin, ALT alanine aminotransferase, AST aspartate aminotransferase, PT prothrombin time, PLT platelet count